On this page
How should a clinical-trial discontinuation notification be written?
Identify the IND and study, the actual sponsor decision, its date and supported reason. State separately whether recruitment, treatment, follow-up and analysis have stopped or continue. Reconcile participant and supply handling and other reporting actions. A study discontinuance report is an IND information-amendment task; it does not automatically withdraw the entire IND.
Before you begin
Sponsor notification regarding a discontinued clinical investigation under an IND; not automatic withdrawal of the entire IND.
What you will prepare: A clear study-specific notification and cross-functional follow-up record.
Say what stopped and what continues
Identify the IND, protocol number and version, study title, population, locations and the effective discontinuation decision. Distinguish stopping recruitment, stopping treatment and ending the investigation. State whether follow-up continues and whether other investigations under the IND remain active.
312.31(a)(2) identifies a clinical-investigation discontinuance report as an information-amendment example. Withdrawal of the entire IND is a different action under 312.38. Do not put a withdrawal instruction into a study-closeout template unless that is the sponsor's actual decision.
Build the explanation from decision and operational records
Collect the sponsor decision, study status, monitoring or committee recommendation where relevant, participant disposition, safety assessment and operational closeout plan. Explain the reason accurately: safety, lack of efficacy, feasibility, business decision or another supported reason. Separate observed findings from the sponsor's interpretation.
A practical notification outline is: study and action; decision date and reason; current enrollment/treatment status; participant safety and follow-up arrangements; investigational-supply handling; communications to investigators/IRBs as applicable; remaining analyses and reporting plan; other affected protocols; requested FDA action or information only. Avoid patient-identifying details in an administrative letter.
If the reason raises a potential expedited safety-reporting obligation, route it immediately to the safety owner. Preparing this notification does not satisfy a separate safety-report requirement.
Worked review: recruitment stopped, follow-up remains
Fictional editorial exercise: enrollment ends for commercial reasons while dosed participants remain in long-term follow-up. A copied letter says the study is complete and all activity has ceased.
Rewrite the status to describe the actual stopped and continuing activities. Align the annual report and planned final report with that disposition. If the stopping reason has not been confirmed by the sponsor decision record, do not infer “no safety concern” merely because operations described a commercial reason.
Describe the stopped activities without erasing continuing work
Use a dated activity record before writing that a study is discontinued or complete. The record below is a preparation aid and should reflect the actual protocol and sponsor decision.
| Activity | Evidence to establish | Wording risk |
|---|---|---|
| Recruitment | Last recruitment activity and whether future enrollment is closed | “Study ended” when only recruitment stopped |
| Investigational treatment | Last dosing status and any continuing treatment arrangements | “All treatment stopped” without checking participant records |
| Safety and other follow-up | Remaining visits, observations and responsible teams | “All activity ceased” while follow-up remains |
| Supply and site closeout | Inventory, return/disposition and site actions | Closeout described as complete while material remains unaccounted for |
| Analysis and final report | Available data, remaining analysis and report plan | A future reporting commitment described as delivered |
| Other protocols and IND | Actual status and scope of the sponsor’s decision | One protocol closure described as whole-IND withdrawal |
Status exercise: new enrollment is closed, treatment has ended, but a long-term safety observation period continues. State each fact and its date. Explain the remaining follow-up and reporting plan. A single “terminated” value in a project tracker cannot substitute for that operational description, and it should not drive an unsupported statement that no participants remain under observation.
Write the reason from the decision record. If the sponsor cites a business decision, say so accurately, but do not infer that there are no safety findings. Ask the safety owner to assess the actual evidence and any separate reporting actions. Conversely, do not rewrite an uncertain finding as a confirmed causal safety conclusion merely because it contributed to the decision.
Section 312.31(a)(2) identifies discontinuance of a clinical investigation as an information-amendment example. An actual withdrawal of the whole IND under §312.38 carries broader consequences, including ending its clinical investigations and notifying current investigators; safety-related withdrawal has additional communication requirements. Establish whether that broader action is intended before using withdrawal language.
Reconcile the final letter with the IND annual report, study reports and controlled clinical records. Link the same decision date and distinguish actual completion from planned work. If the sponsor is withdrawing the IND, use the IND withdrawal guide for that separate action. If the study used an informed-consent exception, review its additional EFIC communication and disclosure duties.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does discontinuing one study automatically withdraw the entire IND?
No. Section 312.31 identifies a study-discontinuance report as an information-amendment example, while §312.38 addresses withdrawal of the IND itself. Confirm which action the sponsor decided to take. Other investigations and ongoing activities must be described accurately rather than closed by implication in a template.
Can the letter say all study activity ceased when safety follow-up continues?
That wording would misdescribe the operational state. Distinguish recruitment, treatment, follow-up, analysis and reporting using the actual records and dates. The notification should explain the discontinued investigation and remaining work; a broad closeout label does not establish that every participant-related activity has ended.
Does a commercial stopping reason establish that there are no safety concerns?
No. The stopping decision and the safety assessment answer different questions. State the sponsor’s documented reason and obtain the relevant safety review rather than inferring a negative finding from a business label. Reconcile the notification with other required reporting and do not use it to conceal unresolved evidence.
What changes if the sponsor is actually withdrawing the IND for safety reasons?
Section 312.38 treats that as a whole-IND action and requires prompt communication of the safety reason to FDA, participating investigators and reviewing IRBs, alongside the broader withdrawal obligations. Establish the real scope and use the appropriate withdrawal process; a single-study discontinuation letter should not silently stand in for it.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR 312.31: information amendments ↗Paragraphs (a)–(c); eCFR current through September 18, 2026.
Regulation
21 CFR 312.38: withdrawal of an IND ↗Whole-IND withdrawal is distinct from a study discontinuation; current through September 18, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.12.9. A heading identifies placement, not mandatory applicability.